FXR Agonism: The Core Mechanistic Platform in PBC and AIH Drug Development

Farnesoid X Receptor (FXR) is the single most frequently addressed therapeutic target across the immune-mediated liver disease patent dataset, with patent families from Terns Pharmaceuticals, Novartis, Metacrine/Organovo, and Intercept Pharmaceuticals all converging on FXR agonism as the central anti-fibrotic and anti-cholestatic mechanism. FXR agonists suppress hepatic bile acid synthesis by downregulating key genes including CYP7A1 and CYP8B1, reduce inflammatory NF-κB signalling, and attenuate hepatic stellate cell activation — three of the principal drivers of progressive fibrosis in both primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH).

The Organovo/Metacrine FXR agonist patents are particularly significant for the immune-mediated liver disease field because they explicitly list autoimmune hepatitis among indications alongside NASH and cholestatic liver disease — a meaningful expansion of the FXR agonist indication landscape beyond its metabolic-disease origins. Novartis AG filings reference tropifexor by name as a specific FXR agonist compound for fibrotic and cirrhotic liver diseases, representing a more advanced development signal relative to unnamed chemical series in other filings. According to WIPO filing data, the breadth of jurisdictional coverage is a reliable proxy for commercial IP protection intent.

Combination Strategies Anchored Around FXR: THRβ, SSAO, ARB, and PPARα/δ

The most intensively protected combination strategy in the immune-mediated liver disease pipeline is the FXR agonist plus thyroid hormone receptor beta (THRβ) agonist dual combination, with Terns Pharmaceuticals filing across at least 8 jurisdictions including US, WO, IL, CA, AU, SG, and TW. RNAseq data embedded in these filings shows the combination downregulates fibrosis-associated genes including Col1a1, Col3a1, Mmp2, Lgals3, Cd68, and Ccr2, while also modulating Treg and M2 macrophage markers including Foxp3, Ikzf2, and Cd163 — a dual anti-fibrotic and immunomodulatory profile. The multi-jurisdictional filing breadth and granularity of RNAseq endpoint data are consistent with IND-stage or Phase 1/2 translation.

“Developers entering the FXR agonist space without related IP positions face significant freedom-to-operate challenges, as FXR agonist-anchored combinations may become the dominant competitive IP landscape in immune-mediated liver disease.”

Terns Pharmaceuticals also files a second distinct combination: FXR agonist plus SSAO (semicarbazide-sensitive amine oxidase) inhibitor, suggesting the company is pursuing multiple combination partner strategies around the same FXR agonist core. Intercept Pharmaceuticals covers obeticholic acid co-administered with angiotensin II receptor blockers (ARBs) for NASH-associated hepatic fibrosis, a mechanistically distinct anti-fibrotic pairing. Meanwhile, Dong-A ST Co., Ltd. describes PPARα/δ agonism combined with FXR agonists or ACC inhibitors for NASH, with functional reduction of α-SMA (activated stellate cells), CCL2, TNFα, and IL-1β beyond single-agent activity. As reported by NIH-funded research, combined nuclear receptor targeting can produce synergistic anti-fibrotic effects that neither agent achieves alone.

Genfit SA files for PPAR agonists in liver failure contexts including acute decompensation (AD), acute-on-chronic liver failure (ACLF), and decompensated cirrhosis — representing one of the more clinically advanced indication contexts described in this dataset. The specificity of these indications (non-compensated cirrhosis with or without ACLF) suggests clinical program definition beyond preclinical hypothesis. The Terns FXR combination filings also identify regulation of retinol metabolism, sphingolipid metabolism, and ABC transporter pathways as additional mechanistic dimensions of the combination regimen.

RNAi and Precision Gene Silencing: HSD17B13, CIDEB, and PNPLA3 as Stratified Targets

RNA interference and antisense oligonucleotide approaches targeting hepatocyte-intrinsic genetic risk modifiers represent the second major modality cluster in this pipeline dataset, with Alnylam Pharmaceuticals and Ionis Pharmaceuticals both filing on HSD17B13 and Alnylam additionally filing on CIDEB. The Alnylam HSD17B13 iRNA program specifies dose ranges of 25–800 mg and defines precise dsRNA sequences (e.g., sense strand 5′-AUGCUUUUGCAUGGACUAUCU-3′), with clinical endpoints including NAFLD activity score (NAS) reduction, ALT normalization, and hepatic steatosis improvement — signals consistent with IND-enabling or Phase 1/2 status.

HSD17B13 (Hydroxysteroid 17β-Dehydrogenase 13) is a hepatic lipid droplet-associated protein whose genetic variants are protective against chronic liver disease. Ionis Pharmaceuticals’ ASO approach covers NAFLD activity score reduction and ALT normalization as primary endpoints. CIDEB (Cell Death-Inducing DFFA-Like Effector B) is targeted by Alnylam via dsRNA and by Regeneron Pharmaceuticals via small molecule inhibitors; the Alnylam filings describe potential combinability with HSD17B13 and PNPLA3 inhibition as a triple-target strategy. The PNPLA3 Ile148Met polymorphism is explicitly cited as a patient stratification criterion — a clear signal of a precision medicine direction. Research published via Nature journals has established the PNPLA3 Ile148Met variant as among the strongest known genetic risk factors for chronic liver disease progression.

Dicerna Pharmaceuticals covers ACC and DGAT2-targeting oligonucleotides for NASH, NAFLD, and — notably — PBC, explicitly including PBC in the disease scope of an RNAi program more commonly associated with metabolic liver disease. Scandinavia Therapeutics files on PKLR gene-silencing polynucleotides for NAFLD and HCC. The emerging interest in genotype-matched combination RNAi therapy — co-inhibiting CIDEB, HSD17B13, and PNPLA3 simultaneously in carriers of risk variants — could influence trial design for both NASH and overlapping immune-mediated liver disease indications.

Immune-Targeted Biologics and Cytokine Biomarkers for AIH, PBC, and PSC

Monoclonal antibodies targeting inflammatory mediators represent a distinct modality cluster in the immune-mediated liver disease pipeline, with ChemomAb Ltd. leading with anti-CCL24 (eotaxin-2) antibodies covering NAFLD, PSC, PBC, NASH, and cholestatic liver disease. The ChemomAb WO patent includes ELISA data from 55 NAFLD patients stratified by Fib4 score, demonstrating elevated circulating CCL24, alongside FACS data for CCR3 expression on peripheral blood mononuclear cells — human translational data suggesting clinical-stage biomarker characterisation. Mechanistically, anti-CCL24 blockade attenuates hepatic stellate cell activation and liver enzyme elevation. According to EMA guidance on biomarker-supported drug development, such translational datasets substantially strengthen regulatory submissions.

The diagnostic biomarker landscape for differential diagnosis of AIH, PBC, and PSC is addressed by Medizinische Hochschule Hannover (Hannover Medical School), which holds 5 patent records across WO, US, EP, CA, and HK jurisdictions covering an eotaxin-anchored cytokine panel. The panel identifies: eotaxin-3 (CCL26) as elevated across all three conditions; eotaxin-1 (CCL11) as elevated specifically in PSC but not PBC or AIH; MDC (CCL22) as lower in all three versus healthy controls; and IL-15 as selectively elevated in AIH — making IL-15 the key discriminating biomarker between AIH and the cholangiopathies. The multi-jurisdictional filing pattern of an academic institution across five commercial jurisdictions suggests active licensing intent.

Gilead Sciences files extensively on LPAR1 (lysophosphatidic acid receptor 1) antagonists for liver fibrosis, with two CN patent families covering triazole carbamate pyridyl sulfonamide and pyrazole derivative scaffolds. Crucially, the Gilead LPAR1 filings explicitly list both PBC and autoimmune hepatitis among hepatic fibrosis indications alongside NASH — a direct extension of LPAR1 antagonism into immune-mediated cholangiopathies. The multi-scaffold approach (two distinct chemical series) suggests active medicinal chemistry optimization. National Cheng Kung University additionally files on anti-IL-20 and anti-IL-20R1 antibodies reducing hepatic TGF-β, CCL2 (MCP-1), and fibrosis markers in CCl4 models, representing an academic translational signal in the cytokine-targeting space.

Cell and Gene Therapy Approaches: CAR-Treg, MSC Microparticles, and MYDGF

Cell and gene therapy modalities represent early-stage but potentially high-differentiation opportunities in the immune-mediated liver disease pipeline, with multiple assignees filing at what appear to be preclinical stages. King’s College London has filed patents on CAR-Treg cells targeting the asialoglycoprotein receptor (ASGR) specifically for autoimmune liver disease including AIH, liver transplant rejection, and liver graft-versus-host disease — a cellular immunotherapy direction not previously prominent in this indication area. ASGR-targeting CAR-Tregs offer the prospect of antigen-specific immune suppression at the hepatic level, potentially offering disease-modifying potential beyond current non-specific immunosuppression with corticosteroids and azathioprine.

Rohto Pharmaceutical Co., Ltd. files two JP patents covering mesenchymal stem cells (MSCs) with high expression of specific miRNAs including miR-210-3p and miR-6846-5p for autoimmune liver disease including AIH, PBC, and PSC. Microparticles derived from these MSCs demonstrate AST/ALT reduction in AIH model mice, providing functional evidence for the approach. Plexogen Inc. files on iPSC-derived MSC exosomes for NASH prevention and treatment, claiming improved efficacy over conventional MSC exosomes. The University of Edinburgh files on alternatively activated macrophage (AAM) therapy for liver injury, with reduction of necrosis, pro-inflammatory cytokines, and fibrosis as described endpoints.

Boehringer Ingelheim International GmbH files two patents (WO and TW) on MYDGF (Myeloid-Derived Growth Factor) protein and gene therapy for liver disorders including viral hepatitis, liver failure, and transplantation — a growth factor-based regenerative direction distinct from current anti-fibrotic or immunosuppressive paradigms. The PatSnap Life Sciences intelligence platform tracks these emerging cell and gene therapy IP positions across all major filing jurisdictions. As noted by WHO in its global hepatitis strategy, novel disease-modifying approaches for autoimmune liver disease represent a critical unmet need given the limitations of existing immunosuppression.

Strategic Implications for IP Positioning and Drug Development in Immune-Mediated Liver Disease

FXR agonism has become a core mechanistic platform in immune-mediated and metabolic liver disease drug development, and the breadth of FXR agonist patent activity across multiple combination partners — THRβ, SSAO inhibitor, ARB, and PPARα/δ — signals that FXR agonist-anchored combinations may become the dominant competitive IP landscape. Developers entering this space without FXR-related IP positions face significant freedom-to-operate challenges. The PatSnap innovation intelligence platform enables systematic freedom-to-operate analysis across all relevant patent families in this space.

AIH and PBC are increasingly addressed directly in FXR agonist and LPAR1 antagonist patent scopes — as evidenced by Organovo and Gilead filings — moving beyond NASH as the primary indication. IP strategists should note that multi-indication FXR and LPAR1 claims covering immune-mediated cholangiopathies represent potential new claim space distinct from NASH-focused patents. The Hannover Medical School eotaxin-3/CCL24/IL-15 cytokine biomarker panel for AIH/PBC/PSC differential diagnosis represents a translational opportunity for companion diagnostic or patient stratification tools; the institution’s multi-jurisdictional patent position across five commercial jurisdictions may create licensing opportunities for developers building clinical programs in this space.

The RNAi targeting of hepatocyte-intrinsic risk genes (HSD17B13, CIDEB, PNPLA3) is entering a genotype-stratified development paradigm, with the combination of multiple risk gene silencing and patient genomic selection signalling a precision medicine direction that could influence trial design for both NASH and overlapping immune-mediated liver disease indications. Cell and gene therapy modalities — CAR-Treg, MSC microparticles, AAV-based approaches, and MYDGF — represent early-stage but potentially high-differentiation opportunities, particularly for AIH where antigen-specific Treg approaches targeting liver-expressed antigens such as ASGR may offer disease-modifying potential beyond current immunosuppression.